JP2023543154A5 - - Google Patents
Info
- Publication number
- JP2023543154A5 JP2023543154A5 JP2023516514A JP2023516514A JP2023543154A5 JP 2023543154 A5 JP2023543154 A5 JP 2023543154A5 JP 2023516514 A JP2023516514 A JP 2023516514A JP 2023516514 A JP2023516514 A JP 2023516514A JP 2023543154 A5 JP2023543154 A5 JP 2023543154A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- mammalian
- seq
- specific regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077339P | 2020-09-11 | 2020-09-11 | |
| US63/077,339 | 2020-09-11 | ||
| PCT/US2021/049914 WO2022056291A1 (en) | 2020-09-11 | 2021-09-10 | Muscle-specific hybrid promoter |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023543154A JP2023543154A (ja) | 2023-10-13 |
| JP2023543154A5 true JP2023543154A5 (enExample) | 2024-09-04 |
| JP7846677B2 JP7846677B2 (ja) | 2026-04-15 |
Family
ID=80629936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516514A Active JP7846677B2 (ja) | 2020-09-11 | 2021-09-10 | 筋特異的ハイブリッドプロモーター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230346976A1 (enExample) |
| EP (1) | EP4211251A4 (enExample) |
| JP (1) | JP7846677B2 (enExample) |
| AU (1) | AU2021342165A1 (enExample) |
| CA (1) | CA3192120A1 (enExample) |
| WO (1) | WO2022056291A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026506177A (ja) | 2023-02-21 | 2026-02-20 | イリューコン セラピューティクス， インコーポレイテッド | 改変インターロイキン２（ｉｌ２）ポリペプチドをコードするポリヌクレオチド、ならびにその作製方法および使用方法 |
| WO2024211480A2 (en) * | 2023-04-05 | 2024-10-10 | Genzyme Corporation | Targeted gene therapy for dm-1 myotonic dystrophy |
| CN121311497A (zh) | 2023-04-14 | 2026-01-09 | 精密生物科学公司 | 肌肉特异性表达盒 |
| WO2025157259A1 (en) * | 2024-01-25 | 2025-07-31 | Sichuan Real & Best Biotech Co., Ltd. | Novel muscle-specific promoters |
| WO2025235807A1 (en) * | 2024-05-10 | 2025-11-13 | Solid Biosciences, Inc. | Compositions and methods to improve graft survival |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1390490B1 (en) * | 2001-05-24 | 2009-04-15 | Genzyme Corporation | Muscle-specific expression vectors |
| AU2015208247B2 (en) * | 2014-01-21 | 2021-05-27 | Universiteit Gent | Muscle-specific nucleic acid regulatory elements and methods and use thereof |
| WO2018178067A1 (en) | 2017-03-27 | 2018-10-04 | Vrije Universiteit Brussel | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof |
| AU2020232790A1 (en) | 2019-03-06 | 2021-09-16 | Generation Bio Co. | Non-active lipid nanoparticles with non-viral, capsid free DNA |
-
2021
- 2021-09-10 WO PCT/US2021/049914 patent/WO2022056291A1/en not_active Ceased
- 2021-09-10 JP JP2023516514A patent/JP7846677B2/ja active Active
- 2021-09-10 CA CA3192120A patent/CA3192120A1/en active Pending
- 2021-09-10 AU AU2021342165A patent/AU2021342165A1/en active Pending
- 2021-09-10 EP EP21867693.0A patent/EP4211251A4/en active Pending
-
2023
- 2023-03-10 US US18/181,796 patent/US20230346976A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7522839B2 (ja) | アデノ随伴ウイルスベクターの製造プロセス | |
| Dolph et al. | The adenovirus tripartite leader may eliminate the requirement for cap-binding protein complex during translation initiation | |
| Jang et al. | An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells | |
| CN111386344B (zh) | 功能性核酸分子及其用途 | |
| JP2024520528A5 (enExample) | ||
| JP2021518150A5 (enExample) | ||
| CN112513250A (zh) | 用于跟踪和操纵细胞rna的融合蛋白和融合核糖核酸 | |
| Xu et al. | SV40 intron, a potent strong intron element that effectively increases transgene expression in transfected Chinese hamster ovary cells | |
| JP7530431B2 (ja) | Ｄｎａ増幅方法 | |
| JP2021519587A5 (enExample) | ||
| JP2024041821A5 (enExample) | ||
| CN104212802B (zh) | 一种肿瘤细胞广谱高活性启动子及其用途 | |
| Estes et al. | Uncovering methods for the prevention of protein aggregation and improvement of product quality in a transient expression system | |
| Mariati et al. | Insertion of core CpG island element into human CMV promoter for enhancing recombinant protein expression stability in CHO cells | |
| US20250066811A1 (en) | DNA Amplification Method Using CARE Elements | |
| JP7846677B2 (ja) | 筋特異的ハイブリッドプロモーター | |
| JP2024523394A5 (enExample) | ||
| Harper et al. | A novel protein factor is required for use of distal alternative 5'splice sites in vitro | |
| CN107245493B (zh) | 一种表达受茶碱调控的适体核酶修饰型sgRNA的载体及应用 | |
| TW202116794A (zh) | 用於生物製造之合成遺傳因子 | |
| JP2024531607A5 (enExample) | ||
| Wang et al. | Shortened nuclear matrix attachment regions are sufficient for replication and maintenance of episomes in mammalian cells | |
| US20250019667A1 (en) | Adenoviral helper plasmid | |
| JP2022518867A5 (enExample) | ||
| Jiang et al. | Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors |